Literature DB >> 21537157

Carnitine deficiency increases susceptibility to bupivacaine-induced cardiotoxicity in rats.

Gail K Wong1, Mark W Crawford.   

Abstract

BACKGROUND: Anecdotal reports suggest that carnitine deficiency increases susceptibility to bupivacaine-induced cardiotoxicity. Bupivacaine inhibits lipid-based respiration in myocardial mitochondria via inhibition of acylcarnitine exchange in rats. The authors hypothesized that carnitine deficiency increases susceptibility to bupivacaine-induced asystole in rats and that acute repletion with L-carnitine reverses this effect.
METHODS: Thirty male Sprague-Dawley rats were assigned to three groups. Rats assigned to the L-carnitine-deficient and L-carnitine-replete groups received subcutaneous D-carnitine on the 10 d before the experiment to induce L-carnitine deficiency. Control rats received an equal volume of subcutaneous normal saline. The rats were anesthetized and mechanically ventilated. Bupivacaine was infused intravenously at a rate of 2.0 mg · kg⁻¹ · min⁻¹ until asystole occurred. The L-carnitine-replete group received intravenous L-carnitine 100 mg · kg⁻¹ immediately before bupivacaine infusion. At asystole, blood was sampled to measure bupivacaine concentration. The primary outcome was time to asystole.
RESULTS: L-carnitine deficiency significantly decreased survival duration (P < 0.0001). Time to bupivacaine-induced asystole decreased by 22% (P < 0.05) in the L-carnitine-deficient group (847 s [787-898]) (median [interquartile range]) compared with controls (1,082 s [969-1,427]). Intravenous administration of L-carnitine completely reversed the reduction in time to asystole. At asystole, the median plasma bupivacaine concentration in the L-carnitine-deficient group was 38% (P < 0.05) less than that in control animals. Plasma bupivacaine concentration was similar in L-carnitine-replete and control animals.
CONCLUSIONS: Carnitine deficiency increased sensitivity to bupivacaine-induced asystole, an effect that was reversed completely by L-carnitine repletion. This study suggests that carnitine deficiency may predispose to bupivacaine-induced cardiotoxicity. L-carnitine may have a protective role against bupivacaine cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537157     DOI: 10.1097/ALN.0b013e31821a8d46

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

1.  Successful treatment of local anaesthetic toxicity using intralipid 20% emulsion following intrathoracic bupivacaine overdose in a cat.

Authors:  Sarah Caulfield; Erica Tinson; Rachael Birkbeck
Journal:  JFMS Open Rep       Date:  2022-06-23

2.  Insulin Signaling in Bupivacaine-induced Cardiac Toxicity: Sensitization during Recovery and Potentiation by Lipid Emulsion.

Authors:  Michael R Fettiplace; Katarzyna Kowal; Richard Ripper; Alexandria Young; Kinga Lis; Israel Rubinstein; Marcelo Bonini; Richard Minshall; Guy Weinberg
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

Review 3.  Carnitine transport and fatty acid oxidation.

Authors:  Nicola Longo; Marta Frigeni; Marzia Pasquali
Journal:  Biochim Biophys Acta       Date:  2016-01-29

4.  Lipid emulsion for local anesthetic systemic toxicity.

Authors:  Sarah Ciechanowicz; Vinod Patil
Journal:  Anesthesiol Res Pract       Date:  2011-09-29

5.  Case report: perioperative management of caesarean section for a parturient with mitochondrial myopathy.

Authors:  Qiang Zheng; Penghui Wei; Jinfeng Zhou; Haipeng Zhou; Fucheng Ji; Wenxi Tang; Jianjun Li
Journal:  BMC Anesthesiol       Date:  2017-07-12       Impact factor: 2.217

Review 6.  Lipid Emulsion for Treating Local Anesthetic Systemic Toxicity.

Authors:  Seong-Ho Ok; Jeong-Min Hong; Soo Hee Lee; Ju-Tae Sohn
Journal:  Int J Med Sci       Date:  2018-05-14       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.